107 related articles for article (PubMed ID: 38611100)
1. Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.
Li L; Li ZZ; Pan LX; Su JY; Huang S; Ma L; Zhong JH
J Clin Transl Hepatol; 2024 May; 12(5):525-533. PubMed ID: 38779519
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma.
Kim SJ; Cummins KC; Tsung A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791931
[TBL] [Abstract][Full Text] [Related]
3. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma.
Du JS; Hsu SH; Wang SN
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611100
[TBL] [Abstract][Full Text] [Related]
4. Advances in postoperative adjuvant therapy for primary liver cancer.
Zeng ZM; Mo N; Zeng J; Ma FC; Jiang YF; Huang HS; Liao XW; Zhu GZ; Ma J; Peng T
World J Gastrointest Oncol; 2022 Sep; 14(9):1604-1621. PubMed ID: 36187393
[TBL] [Abstract][Full Text] [Related]
5. Postoperative therapy options for hepatocellular carcinoma.
Zhong JH; Ma L; Li LQ
Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
[TBL] [Abstract][Full Text] [Related]
6. The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis.
Yang J; Liang H; Hu K; Xiong Z; Cao M; Zhong Z; Yao Z; Deng M
Cancer Cell Int; 2021 Feb; 21(1):92. PubMed ID: 33549093
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.
Zhang W; Zhang B; Chen XP
Front Med; 2021 Apr; 15(2):155-169. PubMed ID: 33754281
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Jeng WJ; Lin CC; Chen WT; Sheen IS; Lin CY; Lin SM
Dig Dis; 2014; 32(6):747-54. PubMed ID: 25376293
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S; Chen M; Cheng AL; Kaseb AO; Kudo M; Lee HC; Yopp AC; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Ma N; Spahn JH; Wang Y; Wu C; Chow PKH;
Lancet; 2023 Nov; 402(10415):1835-1847. PubMed ID: 37871608
[TBL] [Abstract][Full Text] [Related]
10. Survival Benefits From Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma and Microvascular Invasion After Curative Hepatectomy.
Dai MG; Liu SY; Lu WF; Liang L; Ye B
Clin Med Insights Oncol; 2023; 17():11795549231180351. PubMed ID: 37342206
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy.
Feng LH; Zhu YY; Zhou JM; Wang M; Xu WQ; Zhang T; Mao AR; Cong WM; Dong H; Wang L
Front Oncol; 2023; 13():1104492. PubMed ID: 37293583
[TBL] [Abstract][Full Text] [Related]
12. A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study.
Liu ZH; Chai ZT; Feng JK; Hou YC; Zhang XP; Chen ZH; Xiang YJ; Guo WX; Shi J; Cheng SQ
Cancer Med; 2023 May; 12(9):10294-10302. PubMed ID: 36880150
[TBL] [Abstract][Full Text] [Related]
13. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Li SH; Mei J; Cheng Y; Li Q; Wang QX; Fang CK; Lei QC; Huang HK; Cao MR; Luo R; Deng JD; Jiang YC; Zhao RC; Lu LH; Zou JW; Deng M; Lin WP; Guan RG; Wen YH; Li JB; Zheng L; Guo ZX; Ling YH; Chen HW; Zhong C; Wei W; Guo RP
J Clin Oncol; 2023 Apr; 41(10):1898-1908. PubMed ID: 36525610
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
